Penumbra Inc

Penumbra Inc

Develops medical devices for vascular conditions

About Penumbra Inc

Simplify's Rating
Why Penumbra Inc is rated
A-
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Alameda, California

Founded

2004

Overview

Company Historically Provides H1B Sponsorship

Penumbra Inc. specializes in creating medical devices aimed at treating neurovascular and peripheral vascular conditions. Their products include a variety of devices for neuro interventions, such as the Penumbra System and the Penumbra SMART COIL, which are used to address issues like stroke. For peripheral vascular diseases, they offer the Indigo System and related devices. These products are designed to assist healthcare professionals in hospitals and clinics, primarily in Europe and the Americas. What sets Penumbra apart from competitors is their focus on continuous research and development, ensuring their devices meet the changing needs of the medical field. The company's goal is to provide effective and high-quality medical solutions that improve patient outcomes in neurovascular and peripheral vascular care.

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for minimally invasive procedures boosts Penumbra's market potential.
  • Global neurovascular devices market is projected to grow at 8.5% CAGR until 2030.
  • Technological advancements enhance effectiveness of Penumbra's neurovascular treatments.

What critics are saying

  • Leadership gap due to Don Kassing's retirement may affect strategic decisions.
  • Costa Rica manufacturing expansion could face operational challenges and increased costs.
  • Layoffs in Immersive Healthcare division indicate potential strategic instability.

What makes Penumbra Inc unique

  • Penumbra specializes in neurovascular and peripheral vascular medical devices.
  • The company offers innovative solutions for stroke and neurovascular disease treatment.
  • Penumbra's global presence spans North America, Europe, Asia, and Australia.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$116.7k

Below

Industry Average

Funded Over

2 Rounds

IPO funding comparison data is currently unavailable. We're working to provide this information soon!
IPO Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Neuro News International
Feb 28th, 2025
Penumbra launches Access25 delivery microcatheter designed for brain aneurysm access

Penumbra launches Access25 delivery microcatheter designed for brain aneurysm access.

Penumbrainc
Feb 27th, 2025
Penumbra Launches ACCESS25[TM] Delivery Microcatheter Designed for Aneurysm Access and Delivery of Elevated Clinical Benefits

Penumbra recently launched the ACCESS25 Delivery Microcatheter, a single lumen medical device designed to aid physicians in accessing the neurovasculature for the delivery of Penumbra's advanced .020" coil platform.

PR Newswire
Feb 21st, 2025
Penumbra, Inc. Announces Don Kassing Will Retire From Board Of Directors

ALAMEDA, Calif., Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. Kassing joined Penumbra's Board of Directors in 2008 and has served as Presiding Director since 2015."We are grateful for Don's many contributions to the board over the years, particularly his wisdom and guidance in complex situations and through our phases of growth," said Adam Elsesser, board chair, president and chief executive officer of Penumbra. "We also thank Don for his steadfast leadership and dedication to helping Penumbra advance our mission of helping more and more people over the years."Mr. Kassing is President Emeritus of San Jose State University

Investing.com
Feb 19th, 2025
UBS raises Penumbra stock price target to $320, keeps buy rating

Penumbra plans to expand its manufacturing capacity with a new facility in Costa Rica.

PR Newswire
Feb 18th, 2025
Penumbra, Inc. Reports Fourth Quarter And Full Year 2024 Financial Results

ALAMEDA, Calif., Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: Adjusted revenue1 of $321.3 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 12.9% adjusted2 or 13.0% in adjusted constant currency2 compared to the fourth quarter of 2023. Adjusted revenue1 of $1,200.4 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 13.4% in adjusted2 and adjusted constant currency2 compared to the full year 2023

Recently Posted Jobs

Sign up to get curated job recommendations

Penumbra Inc is Hiring for 30 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Penumbra Inc's jobs every few hours, so check again soon! Browse all jobs →